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Abstract
Background: Polypharmacy is an increasing challenge for primary care. Although sometimes clinically justified,
polypharmacy can be inappropriate, leading to undesirable outcomes. Optimising care for polypharmacy necessitates
effective targeting and monitoring of interventions. This requires a valid, reliable measure of polypharmacy, relevant
for all patients, that considers clinical appropriateness and generic prescribing issues applicable across all medications.
Whilst there are several existing measures of potentially inappropriate prescribing, these are not specifically designed
with polypharmacy in mind, can require extensive clinical input to complete, and often cover a limited number of
drugs. The aim of this study was to identify what experts consider to be the key elements of a measure of prescribing
appropriateness in the context of polypharmacy.
Methods: Firstly, we conducted a systematic review to identify generic (not drug specific) prescribing indicators
relevant to polypharmacy appropriateness. Indicators were subject to content analysis to enable categorisation.
Secondly, we convened a panel of 10 clinical experts to review the identified indicators and assess their relative
clinical importance. For each indicator category, a brief evidence summary was developed, based on relevant
clinical and indicator literature, clinical guidance, and opinions obtained from a separate patient discussion panel.
A two-stage RAND/UCLA Appropriateness Method was used to reach consensus amongst the panel on a core set
of indicators of polypharmacy appropriateness.
Results: We identified 20,879 papers for title/abstract screening, obtaining 273 full papers. We extracted 189 generic
indicators, and presented 160 to the panel grouped into 18 classifications (e.g. adherence, dosage, clinical efficacy).
After two stages, during which the panel introduced 18 additional indicators, there was consensus that 134 indicators
were of clinical importance. Following the application of decision rules and further panel consultation, 12 indicators
were placed into the final selection. Panel members particularly valued indicators concerned with adverse drug
reactions, contraindications, drug-drug interactions, and the conduct of medication reviews.
Conclusions: We have identified a set of 12 indicators of clinical importance considered relevant to polypharmacy
appropriateness. Use of these indicators in clinical practice and informatics systems is dependent on their
operationalisation and their utility (e.g. risk stratification, targeting and monitoring polypharmacy interventions)
requires subsequent evaluation.
Trial registration: Registration number: PROSPERO (CRD42016049176).
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Background
The use of multiple medications in a single individ-
ual (polypharmacy) is a global phenomenon, creat-
ing new challenges for many health services [1],
driven by increasing levels of multimorbidity [2] and
a culture of single-condition guideline-based pre-
scribing [3].
Polypharmacy is associated with several undesirable
consequences [4–8]. However, we have previously
demonstrated that the association between polyphar-
macy and adverse outcomes is attenuated in the most
multimorbid individuals [9]. This suggests that overly
simplistic analyses of polypharmacy, relating simple
medication counts to adverse outcomes, may be mis-
leading [9, 10]. Polypharmacy is typically measured
using arbitrary numeric thresholds, but these fail to
capture medication appropriateness; therefore, more
sophisticated approaches accounting for clinical con-
text are required.
A number of prescribing indicators that assess medi-
cation appropriateness are considered to have face val-
idity [11], and may have value in improving quality and
reducing adverse outcomes [12]. However, such indica-
tors generally do not account for multiple drug use
and do not measure polypharmacy per se. In addition,
explicit ‘drug specific’ indicators (e.g. Beers criteria
[13]) do not apply to all patients, and implicit mea-
sures (e.g. the Medication Appropriateness Index [14])
require time consuming input from an experienced
clinician.
There is therefore a need to develop a valid and re-
liable means of measuring polypharmacy that takes
account of clinical appropriateness. Further, a framing
of polypharmacy appropriateness (rather than appro-
priate or inappropriate polypharmacy) acknowledges
a spectrum of prescribing within the context of poly-
pharmacy, including the need to support individua-
lised prescribing approaches where potentially risky
(or ‘inappropriate’) combinations may be fitting for a
particular patient. To be usable in clinical practice,
this measure should ideally focus on generic prescrib-
ing issues (to ensure relevance to all patients, and
avoiding simply focusing on a finite number of medi-
cations, i.e. implicit indicators), whilst still permitting
automation as part of a computerised clinical system.
We anticipate that this measure of polypharmacy
appropriateness would enable more effective targeting
and evaluation of medication optimisation interven-
tions. Used as a first step in identifying which pa-
tients may be at risk of inappropriate prescribing,
such a measure could facilitate targeted conversations
with patients to subsequently ascertain their views on
the appropriateness of their current medication
regimen.
Methods
The aim of this study was to identify the key ele-
ments of a measure of prescribing appropriateness in
the context of polypharmacy. We conducted a sys-
tematic review and RAND/UCLA Appropriateness
Method consensus study, as outlined below. Whilst
our aim was to develop a measure of polypharmacy
appropriateness, the orientation of most measures to
date has been one of inappropriate prescribing, and
we therefore adopt that terminology when referencing
existing approaches.
Systematic review of indicators of polypharmacy
appropriateness
To locate and derive implicit indicators of polypharmacy
appropriateness for consideration by the expert panel,
an initial systematic review was undertaken. The proto-
col was prospectively registered with PROSPERO (regis-
tration number CRD42016049176) [15, 16] and the
manuscript was written in accordance with the PRISMA
statement [17].
Search strategy
We searched Embase, MEDLINE (Ovid), PsycINFO,
CINAHL, Health Management Information Consor-
tium, Cochrane Library, Web of Science, the Trip and
NHS Evidence databases, from 1992 (the year the
Medication Appropriateness Index was first published
[14]) until October 10, 2016. Search terms were de-
veloped in collaboration with an experienced medical
librarian. We used exploded MeSH terms (e.g. in-
appropriate prescribing) and combinations of relevant
keywords and their variants (e.g. medication, drug
therapy, drug utilisation, drug utilisation review, pre-
scribing). We adapted our initial MEDLINE search
strategy (Box 1) to run in the additional databases,
and to perform a review of reviews to identify any
previous reviews in this field (Box 2). Further relevant
publications were identified by a manual search of
references and citations of included papers.
Inclusion criteria
Articles were eligible for inclusion if they reported
the use of a specific tool to assess polypharmacy or
inappropriate prescribing, including both implicit
and explicit indicators. We defined ‘implicit’ (or
‘generic ’) indicators as judgement-based indicators
that facilitate the consideration of the whole pa-
tient, rather than having a narrow focus on specific
drugs or diseases [11]. We defined ‘explicit’ indicators as
criterion-based indicators that assess specific drug-based
or disease-based prescribing against specific standards
derived from guidelines or expert opinion [11].
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The decision to include both implicit and explicit
indicators at full-text screening, rather than includ-
ing only articles stating the focus was on implicit
indicators, was based on our observation that impli-
cit indicators were not always clearly identified as
such. For example, a single implicit indicator may
be embedded within instruments labelled as explicit
indicators, as is the case with the guidelines devel-
oped by Basger et al. [18, 19] in the Australian con-
text. We excluded papers describing non-instrument
based medication reviews, educational interventions,
validation studies of previously published tools, gen-
eral guidelines and recommendations relating to
assessing inappropriate prescribing, and articles not
published in English.
Screening
Publications were assessed for eligibility by title and
abstract screening. An initial random sample of 100
titles/abstracts was triple screened to refine the
application of inclusion and exclusion criteria. A
single reviewer (NE) subsequently screened all titles/
abstracts, with a 10% random sample screened by
two additional reviewers (JB, RP). Any disagree-
ments were resolved by discussion between the
three reviewers. Articles included for full text
screening were retrieved and reviewed against the
inclusion criteria by two reviewers (NE and JB) inde-
pendently, with discrepancies resolved by discussion
with RP.
Box 1 MEDLINE search strategy
(exp Inappropriate prescribing/ or exp. polypharmacy/ or exp.
medication errors/ or exp. Potentially Inappropriate Medication
List/ or (polypharmacy or underprescrib* or under-prescrib* or
over-prescrib* or mis-prescrib* or overprescrib* or misprescrib*
or (beer* adj criteri*) or (pim adj list*)).ti,ab. or ((prescrib* or
prescript* or medicat* or medicin* or drug* or pharm*) adj2
(sub-optimal or suboptimal or optim* or appropriat* or inappropriat*
or unaccept* or accept* or underus* or under-us* or over-us* or
overus* or underutili* or under-utili* or malpractice* or safe* or
unsafe* or danger* or error* or mistak* or (adverse* adj (event* or
effect* or react*)) or harm* or omiss* or omit* or problem*)).ti,ab.)
AND (((exp “Surveys and Questionnaires”/ or exp. guideline/ or
exp. quality assurance, health care/) and ((updat* or develop* or
valid* or creat* or design* or consensus* or Delphi or rand* or
reliab* or interrat* or inter-rate* or (inter adj rate*) or (appropriate*
adj method*)).ti,ab.)) or (((score* or index* or scale* or survey* or
questionnaire* or instrument* or outcome* or tool* or indicat* or
measur* or screen* or criteri* or (quality adj2 assur*) or (patient
adj2 experience*)) adj4 (updat* or develop* or valid* or creat* or
design* or consensus* or Delphi or rand* or reliab* or interrat* or
inter-rate* or (inter adj rate*) or (appropriate* adj method*))).ti,ab.))
Box 2 MEDLINE search strategy for review of reviews
1. ((exp Inappropriate prescribing/ or exp. polypharmacy/ or exp.
medication errors/ or exp. Potentially Inappropriate Medication
List/ or (polypharmacy or underprescrib* or under-prescrib* or
over-prescrib* or mis-prescrib* or overprescrib* or misprescrib*
or (beer* adj criteri*) or (pim adj list*)).ti,ab.) Or ((prescrib* or
prescript* or medicat* or medicin* or drug* or pharm*) adj2
(sub-optimal or suboptimal or optim* or appropriat* or inappropriat*
or unaccept* or accept* or underus* or under-us* or over-us* or
overus* or underutili* or under-utili* or malpractice* or safe* or
unsafe* or danger* or error* or mistak* or (adverse* adj (event* or
effect* or react*)) or harm* or omiss* or omit* or problem*)).ti,ab.)
And ((exp “Surveys and Questionnaires”/ or exp. guideline/ or exp.
quality assurance, health care/) or (score* or index* or scale* or
survey* or questionnaire* or instrument* or outcome* or tool* or
indicat* or measur* or screen* or criteri* or (quality adj2 assur*) or
(patient adj2 experience*)).ti,ab.) and ((updat* or develop* or valid*
or creat* or design* or consensus* or Delphi or rand* or reliab* or
interrat* or inter-rate* or (inter adj rate*) or (appropriate* adj
method*)).ti,ab.)
2. ((exp Inappropriate prescribing/ or exp. polypharmacy/ or exp.
medication errors/ or exp. Potentially Inappropriate Medication
List/ or (polypharmacy or underprescrib* or under-prescrib* or
over-prescrib* or mis-prescrib* or overprescrib* or misprescrib*
or (beer* adj criteri*) or (pim adj list*)).ti,ab.) Or ((prescrib* or
prescript* or medicat* or medicin* or drug* or pharm*) adj2
(sub-optimal or suboptimal or optim* or appropriat* or inappropriat*
or unaccept* or accept* or underus* or under-us* or over-us* or
overus* or underutili* or under-utili* or malpractice* or safe* or
unsafe* or danger* or error* or mistak* or (adverse* adj (event* or
effect* or react*)) or harm* or omiss* or omit* or problem*)).ti,ab.)
And ((exp “Surveys and Questionnaires”/ or exp. guideline/ or exp.
quality assurance, health care/) or (score* or index* or scale* or
survey* or questionnaire* or instrument* or outcome* or tool* or
indicat* or measur* or screen* or criteri* or (quality adj2 assur*) or
(patient adj2 experience*)).ti,ab.) and ((updat* or develop* or valid*
or creat* or design* or consensus* or Delphi or rand* or reliab* or
interrat* or inter-rate* or (inter adj rate*) or (appropriate* adj
method*)).ti,ab.) AND ((systematic adj (review$1 or overview$1)).tw.)
2 not 1
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Extraction of indicators
All full-text papers meeting the inclusion criteria
were reviewed to find implicit indicators of poly-
pharmacy or inappropriate prescribing. Indicators
were extracted and subjected to qualitative content
analysis to identify categories into which they could
be grouped [20]. Two authors (JB and RP) inde-
pendently reviewed all indicators and generated a
coding framework, which was refined through con-
sensus discussions to produce a final set of indica-
tor categories. Indicators that, on further scrutiny,
were deemed not to be truly implicit were excluded
at this stage. All indicators, within their categories,
were subsequently taken forward for expert review
in a consensus panel.
Quality assessment of indicators
Where stated, the development method for the identi-
fied indicators was extracted, and its strengths and
limitations were assessed with reference to the Joanna
Briggs Institute critical appraisal checklist for text and
opinion [21].
Expert consensus process
The two-stage RAND/UCLA Appropriateness Method
was employed to reach consensus on indicators of pre-
scribing considered by experts to be key to a measure
of polypharmacy appropriateness. The RAND/UCLA
Appropriateness Method is a well-established approach
for systematically generating expert consensus by com-
bining scientific evidence with expert opinion, and sub-
sequently aggregating individual opinions into a single
perspective [22].
Patient views
We convened a panel of five patient representatives
from a local ‘patient and public involvement in re-
search’ group to gather their views on which aspects
of polypharmacy and prescribing identified by the
systematic review were of particular relevance and
concern to them. The panel meeting was facilitated
by a general practitioner (RP), with support from a
specialist Patient and Public Involvement coordin-
ator responsible for facilitating patient involvement
in research [23]. The categories of polypharmacy or
inappropriate prescribing into which the identified
indicators had been grouped were presented to the
panel, and discussion encouraged around the par-
ticular importance or relevance of this area to the
patient experience. Patient representatives were
asked, in particular, to reflect on the relevance and
importance of each prescribing indicator category,
whether doing something about it would make a
difference, the potential challenges of measuring it,
and whether they would prioritise one or more cat-
egories. Field notes were taken during the conduct
of the panel meeting and key points across each
category were summarised. A synopsis of the patient
views in relation to each category was presented in
narrative form in the evidence summaries supplied
to the expert panel (see below).
Evidence summaries
For each indicator category, the research team de-
veloped a corresponding brief evidence summary.
These summaries drew upon clinical and academic
literature, and addressed the importance and rele-
vance of the issue in relation to polypharmacy, the
potential consequences for patients, and how the in-
dicators had been developed and evaluated. As out-
lined above, patient views were also incorporated
based on the earlier patient panel discussion. Evi-
dence summaries were then presented to panel
members to support discussions as part of the
RAND/UCLA Appropriateness Method consensus
exercise; these included a brief summary of the
strengths and weaknesses of the approach to deriv-
ing each included indicator, as derived from the
quality assessment of indicators.
Expert panel members
We undertook a snowball approach to recruit expert
panel members, aiming to include a range of profes-
sions and levels of experience. We particularly fo-
cused on individuals immersed in the general
prescribing process and those who regularly dealt
with polypharmacy; we therefore targeted general
practice, pharmacy, pharmacology, and geriatric
medicine. We therefore approached relevant profes-
sional organisations, including the Royal College of
General Practitioners, Royal Pharmaceutical Society,
British Pharmacological Society, and additional known
contacts of the research team. Our final ten-member
panel consisted of four general practitioners, two
pharmacists, three geriatricians, and one clinical
pharmacologist; RAND/UCLA approaches typically
include anything from 7 to 15 members in a panel
[22]. Panel members were not involved in the system-
atic review itself.
First stage assessment
In stage one, we asked panel members to participate
in an online survey to evaluate the implicit indicators
of inappropriate prescribing or polypharmacy identi-
fied through the systematic review. Panel members
were sent a personalised link to complete the first
stage of ratings using the survey software, Qualtrics
(https://www.qualtrics.com). Indicators were presented
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to panel members in their category groupings. Panel
members were asked to review the indicators within
each category and score each indicator in turn in
relation to (1) its clinical importance with regards to
polypharmacy and (2) its clarity, using a rating scale
numbered 1 to 9, where a score of 1 meant the indi-
cator was extremely unimportant (or unclear) in
evaluating polypharmacy appropriateness, and a score
of 9 meant the indicator was extremely important
(and clear). Consensus classifications for each indica-
tor were established using a series of rules, outlined
in Table 1.
Second stage assessment
In stage two, we convened a face-to-face meeting of
all panel members to further review and discuss in-
dicators and their scores. The meeting was facilitated
by an experienced RAND/UCLA Appropriateness
Method facilitator (SC) with input from a general
practitioner with expertise in polypharmacy (RP).
Anonymised frequency distributions and median
scores for the clinical importance rating of every
stage one indicator were provided to each panel
member at the start of the meeting, alongside the
scores they had themselves assigned to every indica-
tor. Categories of indicator were discussed, in turn,
with panel members given the opportunity to sug-
gest changes to the wording of the indicators; the
wording of all new variations of indicators needed
to be agreed by all panellists. At the end of discus-
sions around each category, panel members were
asked to rate each indicator again, including new
variations, in relation to their clinical importance to
polypharmacy.
Application of final decision rules
As indicators considered by the panel were pre-
sented in categorical groupings, many indicators,
whilst drawn from different sources, were closely
related. To ensure our final indicator set was a
non-duplicative measure of polypharmacy appropri-
ateness, we took the following steps. First, in order
to decide which of the highest scoring indicators
within each category to take forward to the final set,
two members of the research team (JB and RP) inde-
pendently coded indicators within each category
grouping to identify sub-category groupings, which
were further refined through discussion with two
other team members (AA and SR). The highest scor-
ing indicator from each sub-category grouping was
subsequently taken forward; all such indicators
scored a minimum of 7. Where more than one indi-
cator in each sub-category had the same highest
score, the decision as to which indicator to select
was made within the research team through discus-
sion and consideration of the likely feasibility of the
operationalisation of that indicator in primary care.
We then applied the following decision rules to the
remaining indicators:
1. Able to be applied at the level of individual drugs
2. Not overlapping with or duplicating another
indicator
The final suggested list was circulated to the panel
members for any last comments and review.
Results
Systematic review
Our review identified 20,879 papers for title/abstract
screening, from which 273 full-text papers were
identified for review (Fig. 1). Double screening of a
10% random sample of all citations had a 97% con-
sensus rate, with both reviewers making the same
decision. Following full text screening, we selected
17 papers that included either all implicit or a mix-
ture of implicit and explicit indicators. A further
five papers were identified through forward and
backward citation searching of the 17 papers. From
the resulting 22 papers (Appendix 1), we identified
189 potential implicit indicators of polypharmacy or
inappropriate prescribing. On further scrutiny, 29
indicators did not meet our inclusion criteria. The
remaining 160 indicators (Additional file 1) were
placed into 18 categories derived through content
analysis (Box 3). The wording of each indicator
remained unchanged from its original source and
thus, at this stage, categories could contain similar
Table 1 Rules used to determine consensus classification for
panel ratings
Median panel
score
Criteria for:
Disagreement Equivocal Agreement
> 20% of individual
scores equal to:
20% of individual
scores equal to:
1 4–9 4–9
2 5–9 5–9
3 6–9 6–9
4 ≥ 33% of individual
scores equal to 1–3
AND
≥ 33% of individual
scores equal to 7–9
1, 7–9 1, 7–9
5 1, 2, 8, 9 1, 2, 8, 9
6 1–3, 9 1–3, 9
7 1–4 1–4
8 1–5 1–5
9 1–6 1–6
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indicators varying only slightly in their wording or
grammatical construction.
Patient panel
Although patient representatives discussed all of the
prescribing indicator categories, they prioritised ad-
herence, drug–drug interactions and clinical efficacy
as fundamental to polypharmacy appropriateness.
They raised concerns about how feasible it was to
evaluate adherence, but felt it was a central issue
for patients managing complex medication regimens.
The avoidance of adverse drug–.drug interactions
was also seen as vital; the patient panel stated that
they looked to clinical expertise to evaluate and
avoid these risks for patients. Finally, discussions on
the role of clinical efficacy focused on how specific
this was to the individual, and patient representa-
tives voiced concerns raised about how clinicians
could evaluate and optimise the overall efficacy of a
complex medical regimen for each patient.
Cost-effectiveness was seen as relevant but not a
core consideration, although patient representatives
Fig. 1 PRISMA Diagram showing review process
Box 3 Prescribing indicator categories, derived from
content analysis of identified indicators
1. Adherence
2. Adverse drug reactions
3. Drug-drug interactions
4. Medication review
5. Contraindication (drug-disease interactions)
6. Alternatives to current therapy
7. Clinical efficacy
8. Complexity of medication
9. Compliance with guidance
10. Cost-effectiveness
11. Directions
12. Dosage/duration
13. Duplication
14. Other inappropriate prescribing
15. Indication
16. Under-prescribing
17. Specific safety issues
18. General indicators
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agreed with the prescribing of generic medications
where possible.
RAND/UCLA Appropriateness Method
In stage one, the 160 indicators identified from the sys-
tematic review were presented to the panel for consid-
eration and rating. In the stage two face-to-face
meeting, panel discussions led to the introduction
of 18 re-worded or new indicators, giving a total
pool of 178 indicators for consideration. There was
panel consensus that 134 indicators were of clinical
importance (scoring a median rating of 7 or above);
for a further 5 indicators, the panel was equivocal
as to clinical importance. The panel agreed that 19
indicators were not of clinical importance, and they
did not reach consensus about the importance of 20
indicators. There was a notable lack of prioritisation
of, and consensus around, indicators relating to
cost-effectiveness, and all indicators in this group
were eliminated at this stage.
The remaining 134 indicators represented 17 cat-
egories, from which we derived 29 sub-categories.
Application of the agreed decision rules led to a final
listing of 12 indicators (Table 2 and Box 4), which,
in consultation with the panel, were re-worded to be
consistent in the use of terminology (e.g. ‘drug’ ra-
ther than ‘medication’), grammar (e.g. statements ra-
ther than questions) and positive-versus-negative
framing. These came from nine previously developed
indicator lists (one indicator from each of seven
existing lists [14, 24–29] and two indicators each
from a further two lists [30, 31]). The panel intro-
duced one entirely new indicator during stage two
discussions. The final suggested list was circulated to
the panel members for final comment and agree-
ment; minor rewording was suggested and agreed for
three indicators as a result (indicators 2, 7, and 11),
most notably the insertion of ‘hepatic status’ into in-
dicator 7 (the drug as currently prescribed is not
likely to be sub-therapeutic or toxic, based on the
dose, route and dosing interval for the age, renal and
hepatic status of the patient).
Discussion
We have identified a set of 12 indicators of prescribing
appropriateness suitable for use in the context of a pa-
tient with polypharmacy. We are currently operationa-
lising these indicators for use in clinical practice and
informatics systems, with the aim of facilitating risk
stratification, and the targeting and monitoring of
polypharmacy interventions.
Our review identified a proliferation of implicit in-
dicators of inappropriate prescribing; our final set of
12 indicators of polypharmacy appropriateness origi-
nated from nine different existing measures, includ-
ing the influential Medication Appropriateness Index
(MAI) [14, 32]. The MAI is comprised of 10 ques-
tions, completed by a pharmacist or physician in
order to assess the appropriateness of a drug. It has
been widely used as an outcome measure in rando-
mised trials of interventions to improve prescribing;
however, its authors specifically state that, whilst it
is suited to identifying instances of potentially in-
appropriate prescribing, it was not developed to
identify sub-optimal prescribing in the context of
polypharmacy [32]. Whilst only one of our indicators
was directly derived from those within the MAI, it is
important to note that our final list overlaps with
the MAI in many ways, suggesting both that a num-
ber of core constructs of inappropriate polypharmacy
(including indication, effectiveness and interactions)
were captured well by this measure, and that subse-
quent measures of inappropriate prescribing may
have been replicating much of the original MAI
work.
However, areas of clinical importance not captured
by the MAI were also selected by our expert panel,
reflecting our particular focus on the context of
Box 4 Final indicators as agreed by expert panel
Implicit indicators of polypharmacy appropriateness
For this specific drug:
1. The indication for the drug is recorded in the medical record
2. There are no effective non-pharmacological alternatives
available
3. Drug selection is consistent with established clinical practice
4. There are no clinically significant drug-drug interactions
(including duplication of therapy)
5. If the drug is contraindicated, the prescriber gives a valid
reason
6. The drug is effective in this patient for this indication
7. The drug, as currently prescribed, is not likely to be sub-
therapeutic or toxic, based on the dose, route and dosing
interval for the age, renal and hepatic status of the patient
8. The drug regimen cannot be simplified
9. The patient/caregiver is clear about the drug regimen
10. The patient adheres to the drug schedule
11. The drug treatment is reviewed by an appropriate clinician
at least once per year, or more frequently if in accordance with
best clinical practice
12. If an adverse drug reaction occurs, there are details given of
the reaction and recommended future monitoring in the
medical record
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multiple medications. These included patient adher-
ence, the complexity of the medication regimen and
the availability of non-pharmacological alternatives.
Determinants of patient adherence are complex; spe-
cific factors, including frequent dosing, longer dur-
ation of treatment and the presence of adverse
effects, may all decrease adherence [33]. Medication
regimen complexity is negatively associated with levels
of adherence in patients, and medications become in-
creasingly complex with increasing levels of polyphar-
macy [34]. Increased toxicity as a consequence of multiple
medicines [35] may be reduced by using other treatment
options. Lifestyle measures and non-pharmacological
treatments are key alternative therapeutic options for a
range of clinical conditions commonly found in patients
with polypharmacy, including depression and cardiovascu-
lar risk management [36, 37].
The importance of a regular full review of prescribed
medications was formulated as a new indicator specif-
ically following panel discussion. Systematically con-
ducted medication reviews have been shown to be of
particular importance to patients with polypharmacy
[38] and have been recommended for those over 75
taking multiple drugs. Not conducting regular medi-
cation reviews, particularly for those prescribed
multiple drugs, places patients at greater risk of po-
tential harm [39]. However, current evidence is lim-
ited on the clinical effectiveness of systematically
conducted medication review for reducing the sub-
optimal use of medicines and improving patient-reported
outcomes [40].
Cost-effectiveness was included in a number of
identified instruments, including the MAI, but
discarded by our panel. Their view was that
cost-effectiveness in prescribing (typically defined as
ensuring that medication is both clinically and eco-
nomically appropriate for the conditions [41]) was
not, in itself, a marker of polypharmacy appropri-
ateness; instead, they viewed cost-effectiveness as a
potentially positive consequence of patient-centred
medicines optimisation. Our patient panel, too,
echoed this opinion, agreeing simply that the pre-
scribing of generic drugs, when available and when
cheaper than branded products, was a sensible
approach.
A number of strengths and limitations of this
study are worth acknowledging. We have conducted
a large-scale systematic review, supported by an
experienced medical librarian, and followed a
well-established consensus method with a diverse
expert panel. As polypharmacy is relevant to all
ages, we placed no restrictions on age in our ana-
lyses in order to ensure the generalisability of the
findings. To locate all potentially relevant indicators,
we used a high sensitivity, low precision search
strategy; we acknowledge the subsequent high cit-
ation screening workload (with only 10% double
screening) may have therefore resulted in important
relevant citations being missed. Most of the indica-
tors located, reviewed and evaluated for clinical im-
portance had previously been subject to robust
development processes, increasing our confidence in
their face and content validity. However, we note
that it is possible we missed additional relevant
indicators if they were not readily identifiable as
implicit measures of appropriate prescribing or
polypharmacy. Whilst we recruited a wide range of
experts to the panel, they may not be representative
of all healthcare professionals involved in caring for
patients with polypharmacy. The lack of inter-
national perspectives on the panel, which was con-
vened only from UK participants, may reduce the
applicability of our findings to other contexts. Fol-
lowing our stage two panel meeting, we developed
and applied additional decision rules to produce a
non-duplicative and coherent indicator list; whilst
this was done in consultation with the panel, we
acknowledge that other research teams may have
made different decisions about which indicators to
retain. Additional work will be necessary to explore
the acceptability and operationalisation of the
chosen indicators within clinical systems, and to
ascertain their utility for risk stratification, targeting
and monitoring of polypharmacy interventions. This
work will additionally consider issues such as
whether indicators should be weighted in an assess-
ment of polypharmacy appropriateness. Finally, we
note that this approach does not by itself facilitate
the inclusion of patient perspectives of polyphar-
macy appropriateness. Whilst our proposed meas-
ure, when operationalised, may highlight patients
where there are clinical concerns about medication
regimen, it cannot offer a holistic assessment of the
appropriateness of the regimen, where the patients’
perspectives must be central to any decisions about
care.
Conclusions
This study has integrated and adapted existing indicators
of appropriate prescribing, and introduced a new one, to
produce a short, yet comprehensive list of 12 indicators
suitable to the assessment of prescribing appropriateness
in a patient with polypharmacy. Use of these indicators
in clinical practice and informatics systems is dependent
on their operationalisation, and their utility (e.g. risk
stratification, targeting and monitoring polypharmacy
interventions) requires subsequent evaluation.
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